Anti-N6-methyladenosine (m6A), Recombinant [17-3-4-1]
Invented at University of Nottingham
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153275 |
| Applications | IP DB |
| Antigen/Gene or Protein Targets | N6-methyladenosine-5'-mono-phosphate |
| Reactivity | Human, Mouse and Saccharomyces cerevisiae |
| Relevance |
Recombinant monoclonal antibody which binds to m6A modification found in RNA and allows for analysis of methylated transcriptomes. This can be used to investigate how m6A modifications regulates gene expression. Background and Research Application N6-Methyladenosine (m6A) is an abundant modification found in mRNA, tRNA, snRNA, as well as long non-coding RNA, in all species. RNA adenosine methylation is catalysed by a multicomponent complex composed of METTL3/MT-A70, METTL14, and WTAP in mammals. METTL3 & METTL14 are responsible for the methyltransferase activity of the complex, and WTAP mediates substrate recruitment. The m6A antibody was created to identify m6A containing messages within RNA and helped identify the transcripts of three key, early regulators of meiosis, IME1, IME2 and IME4 itself as being methylated in RNA transcripts. This is a recombinant version of the anti-N6-methyladenosine monoclonal antibody. Anti-m6A. helped narrow down the position of m6A in IME2 as towards the 3’ end. Anti-N6-methyladenosine will allow for analysis of methylated transcriptomes, and could aid understanding in how the m6A base modification regulates gene expression. |
| Host | Mouse |
| Immunogen | Hapten N6-methyladenosine-5'-mono-phosphate conjugated to BSA of all N6-methyladenosine |
| Subclass | IgG1 kappa |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Research Area | Epigenetics & Nuclear Signalling |
| Immunogen UniProt ID | Q8BGW1 |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest It was shown that mutations in the m6A demethylase gene FTO, which cause a decrease of m6A levels, are associated with an increased risk for obesity and type 2 diabetes. This antibody recognises N6-methyladenosine in both modified RNA AND DNA (see associated data). Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Application Note: For immunoprecipitation the best results are obtained by pre-binding the antibody to the beads before washing off unbound immunoglobulin. It is recommended to start with an excess of antibody in order to ensure the Protein G beads are saturated. IP protocol was derived from Dominissini et al., 2013 Nat Protoc. 8(1):176-89. Concentration 1mg/ml as standard Related Six products based on this clone: - Anti-N6-methyladenosine [17-3-4-1], Mouse IgG1, Lambda - Anti-N6-methyladenosine [17-3-4-1], Rabbit IgG, Lambda - Anti-N6-methyladenosine [17-3-4-1], Human IgG4-S228P, Lambda - Anti-N6-methyladenosine [17-3-4-1], Human IgG1, Lambda - Anti-N6-methyladenosine [17-3-4-1], Human IgG1, Lambda, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors - Anti-N6-methyladenosine [17-3-4-1], Mouse IgG2a, Lambda |
References: 1 entry
Original hybridoma first published in: Bodi et al. 2010. Nucleic Acids Res. 38(16):5327-35. PMID: 20421205.
Add a reference
References: 1 entry
Original hybridoma first published in: Bodi et al. 2010. Nucleic Acids Res. 38(16):5327-35. PMID: 20421205.
Add a reference
